Illustrative image – not actual.Lupin has earmarked Rs 200 crore to set up three manufacturing facilities in Indore in Madhya Pradesh by March 2011.
The company is developing 25 products each in dermatology and ophthalmic lines and thus it plans to set up new facilities.
Besides, the company plans to acquire established brands in the US market, in segments like paediatric and primary care. It has recently got clearance from the US Food and Drug Administration for its Mandideep production unit in Madhya Pradesh. This unit is likely to help Lupin continue production and export of drugs to the US.
